ArticleFrontiers in pharmacology2023

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.

Daniel Morales-Cano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.